DVAX News 1.50 Dynavax Technologies Corp (DVAX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dynavax Technologies Corp (DVAX) 1.50 $DVAX

Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).

What Falling Estimates & Price Mean for Discovery Laboratories (DSCO) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:33AM CDT
A stock that investors may want to consider dropping is Discovery Laboratories Inc. (DSCO)

Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 3:10PM CDT
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B

Dynavax Technologies Down 5.3%, Shares Slide into the Red (DVAX)
Comtex SmarTrend(R) - Tue Apr 15, 12:47PM CDT
Dynavax Technologies (NASDAQ VAX) is one of today's worst performing low-priced stocks, down 5.3% to $1.42 on 1.1x average daily volume. Dynavax Technologies has traded 3.4 million shares thus far today, vs. average volume of 3.2 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.2%) and underperformed the S&P 500 (-5.3% to the S&P's -0.2%) during today's trading.

Tuesday’s Top Health Care Stories: Johnson & Johnson, Teva, Mylan, and Dynavax
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 15, 8:24AM CDT
Let's take a quick look at four stocks -- Johnson & Johnson , Teva , Mylan , and Dynavax -- which could all loom large in health care news this Tuesday morning. Johnson & Johnson reports first quarter earnings, raises...

Dynavax Initiates Phase 3 Study of HEPLISAV-B(TM)
Marketwire - Tue Apr 15, 5:01AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study (known as HBV-23) was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to Dynavax by the U.S. Food and Drug Administration in February, 2013.

Health Care Sector Stocks under Review -- Research on Endo Intl., Dynavax Technologies, Forest Laboratories, and Orexigen Therapeutics
PR Newswire - Wed Apr 09, 9:14AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average advanced 0.06% to 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 4.04% in the last one month. Investor-Edge has initiated coverage on the following equities: Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP, DVAX, FRX and OREX can be downloaded upon signing up at:

Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches
M2 - Tue Mar 25, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/398z3d/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022" report to their offering. Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from approximately $959.9 million in 2012 to $1.19 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.2%. Out of the eight major markets the US, Canada, France, Germany, Italy, Spain, the UK and Japan the majority of HBV vaccine sales will take place in the US, which will boast a higher CAGR of 3.4% and expand its market share from 55% to 61.7% during the forecast period. The US will be followed by Canada and the five European countries, with expected CAGRs of 1% and 0.5%, respectively. The growth in HBV vaccine sales will result from the launch of Dynavax Technologies' Heplisav and Sanofi Pasteur MSD's Hexyon, with peak-year sales anticipated to reach $85 million and $520 million, respectively. Christopher Pace, Ph.D., The report Analyst covering Infectious Diseases, says: Dynavax hopes to leverage Heplisav's superior immunogenicity and dosing regimen to increase HBV vaccine uptake in the adult market. On the other hand, Sanofi Pasteur MSD is positioning Hexyon to be the first fully liquid pediatric hexavalent vaccine. However, the authors believe that inadequate HBV vaccination coverage rates in certain high-risk populations represents one of the most important unmet needs in the marketplace. Pace says: In the pediatric segment, companies are leveraging combination vaccines to increase HBV vaccine uptake, while improved dosing regimens are necessary to increase vaccination coverage rates in adults. For both children and adults, these companies must ensure that physicians understand immunization recommendations and are able to effectively identify patients. Overall, ensuring high coverage rates will be essential to the commercial success of HBV vaccines during the forecast period. This report provides an overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data. It also gives annualized HBV vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 to 2022. Key Topics Covered: List of Tables List of Figures Introduction Disease Overview Vaccination Recommendations and Coverage Rates Competitive Assessment Opportunity and Unmet Need Pipeline Assessment Current and Future Players Market Outlook Appendix Companies Mentioned GSK Merck Sanofi Kaketsuken Dynavax Technologies For more information visit http://www.researchandmarkets.com/research/39...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...

Health Car Sector Equities Technical Insight -- Research on Dynavax Technologies, Forest Laboratories, Orexigen Therapeutics and Endo Inl.
PR Newswire - Fri Mar 21, 9:08AM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 7.91% in the last three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC (NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP can be downloaded upon signing up at:

Looking for Bargain Biotechs? Consider Small-Cap Vaccine Makers
George Budwell, The Motley Fool - Motley Fool - Wed Mar 12, 5:30PM CDT
Growth and value are two words that have completely fallen out of the biotech lexicon of late. The adjectives 'bubble' and 'expensive' have instead taken their place, when investors talk biotech. And with the average biotech price to earnings ratio...

Wider Q4 Loss at Dynavax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:10AM CDT
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.

Dynavax Reports Fourth Quarter and Year End 2013 Financial Results
Marketwire - Mon Mar 10, 3:01PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2013. The Company had $189.4 million in cash, cash equivalents and marketable securities as of December 31, 2013.

Scandal-Ridden SAC Capital Buys Broadcom, Dynavax, and Boston Scientific
Selena Maranjian, The Motley Fool - Motley Fool - Fri Mar 07, 4:44PM CST
The latest 13F season has arrived, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and selling....

Will Dynavax (DVAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:19AM CST
Will Dynavax (DVAX) Continue to Surge Higher?

Dynavax Receives Milestone Payments from AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 10:40AM CST
Dynavax Technologies recently received a $5.4 million milestone payment from collaboration partner AstraZeneca.

Dynavax to receive USD5.4m milestone payment from AstraZeneca under the Phase 1 clinical study of AZD1419
M2 - Tue Mar 04, 7:06AM CST
Biopharmaceutical company Dynavax Technologies (NASDAQ VAX) revealed on Monday the receipt of a USD5.4m milestone payment from its biopharmaceutical business collaborator, AstraZeneca.

Dynavax to Receive $5.4 Million Milestone
Marketwire - Mon Mar 03, 3:00PM CST
Dynavax Technologies Corp. (NASDAQ: DVAX) today announced a $5.4 million milestone payment from its collaborator, AstraZeneca. The companies also amended their research collaboration and license agreement to transfer responsibility for conduct of further clinical trials from Dynavax to AstraZeneca, following completion of the ongoing Phase 1 clinical study of AZD1419 for the treatment of asthma.

Dynavax to Present at the 34th Annual Cowen & Company Health Care Conference
Marketwire - Fri Feb 28, 3:00PM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 34th Annual Cowen & Company Health Care Conference in Boston on Tuesday, March 4, 2014 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time).

SINA Q4 Makes More Money
SinoCast - Tue Feb 25, 4:21AM CST
SINA Corporation (Nasdaq: SINA) revealed net operating revenue of USD 197 million in fourth quarter ended December 31, 2013, rising 42% from a year earlier. Net profit reached USD 44.5 million, in contrast to USD 2.4 million a year earlier, representing USD 0.59 per share after being diluted, in contrast to USD 0.03 a year ago.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 26

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 17

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 150

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 59

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Mastering Prescription Labels: Critical Insights for Safety

Updated Category News Views 45

Revolutionizing How We Approach Prescription Labels Prescription labels aren't just scraps of paper or stickers slapped on bottles; they're lifelines. The insight from pharmacy expert Sheldon Birch could turn a regular label into a powerful tool for health management. According to Birch, the label is often disregarded yet speaks volumes about the medication you've got in...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 100

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 109

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 12

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading

Top 5 Most Recently Viewed Articles

BexBack Launches High-Leverage Trading with Exciting Bonuses

Updated Category News Views 176

Exciting New Trading Features from BexBack BexBack, a leading cryptocurrency exchange platform, is thrilled to reveal its latest trading enhancements, designed for traders eager to amplify their market position. These innovative features are now accessible to users across the globe, marking a significant step in meeting the soaring demand for high-leverage crypto trading....

Continue Reading
BigBear.ai Partners for AI Innovation Amid Stock Surge

Updated Category News Views 208

BigBear.ai Stock Rises Dramatically BigBear.ai, Inc. (NASDAQ:BBAI) shares have experienced a substantial increase recently. This surge comes after the company announced a significant partnership aimed at enhancing its AI solutions tailored to national security needs. The latest development involves collaboration with another entity to create advanced AI-enabled hardware....

Continue Reading
Totalkredit A/S Unveils Latest Prepayment Data Insights

Updated Category News Views 289

Understanding Recent Prepayment Updates from Totalkredit A/S To all interested parties, Prepayments (CK93) In adherence to the Danish Capital Markets Act, Totalkredit A/S has made available its latest prepayment data. This release reflects the status as of May 2, 2025, and is presented in an accessible format. This information will be efficiently distributed through...

Continue Reading
Examining Coherent's Earnings Outlook and Market Trends

Updated Category News Views 126

Anticipating Coherent's Earnings Report Coherent (NYSE: COHR) is preparing to announce its quarterly earnings soon. Investors are keenly observing the financial landscape to glean insights prior to the release. Analysts predict an earnings per share (EPS) of $0.84, setting the stage for interesting discussions. Investor Expectations Optimism surrounds the forthcoming...

Continue Reading
Exciting Leadership Change at Focus Financial Partners Inc.

Updated Category News Views 319

Leadership Transition at Focus Financial Partners Focus Financial Partners Inc., a prominent player in wealth management and related financial services, has announced a significant leadership change with the appointment of Jason Dubinsky as the new Chief Financial Officer. This transition marks an important chapter for the company, with Mr. Dubinsky set to join in March....

Continue Reading